These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35566603)

  • 1. Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis.
    Özdirik B; Maibier M; Scherf M; Nicklaus JM; Frohme J; Puengel T; Meyer Zum Büschenfelde D; Tacke F; Mueller T; Sigal M
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
    Loosen SH; Breuer A; Tacke F; Kather JN; Gorgulho J; Alizai PH; Bednarsch J; Roeth AA; Lurje G; Schmitz SM; Brozat JF; Paffenholz P; Vucur M; Ritz T; Koch A; Trautwein C; Ulmer TF; Roderburg C; Longerich T; Neumann UP; Luedde T
    JHEP Rep; 2020 Apr; 2(2):100080. PubMed ID: 32140677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
    Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
    J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.
    Sjöwall C; Martinsson K; Cardell K; Ekstedt M; Kechagias S
    Transl Res; 2015 Jun; 165(6):658-66. PubMed ID: 25445207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection.
    Berres ML; Schlosser B; Berg T; Trautwein C; Wasmuth HE
    J Clin Gastroenterol; 2012 Apr; 46(4):334-8. PubMed ID: 21934527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis.
    Zhang Q; Li L; Chen H; Zhang G; Zhu S; Kong R; Chen H; Wang G; Sun B
    J Clin Lab Anal; 2020 Mar; 34(3):e23097. PubMed ID: 31774228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
    Koch A; Zimmermann HW; Gassler N; Jochum C; Weiskirchen R; Bruensing J; Buendgens L; Dückers H; Bruns T; Gerken G; Neumann UP; Adams DH; Trautwein C; Canbay A; Tacke F
    Liver Int; 2014 Oct; 34(9):1330-9. PubMed ID: 24575897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum soluble urokinase plasminogen activator receptor in alcoholics: relation to liver disease severity, fibrogenesis, and alcohol use.
    Tuomi H; Kultti J; Danielsson J; Kangastupa P; Akerman K; Niemelä O
    J Gastroenterol Hepatol; 2014 Dec; 29(12):1991-5. PubMed ID: 24909734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS.
    Loosen SH; Benz F; Mohr R; Reuken PA; Wirtz TH; Junker L; Jansen C; Meyer C; Praktiknjo M; Wree A; Reißing J; Demir M; Gu W; Vucur M; Schierwagen R; Stallmach A; Kunstein A; Bode J; Trautwein C; Tacke F; Luedde T; Bruns T; Trebicka J; Roderburg C
    JHEP Rep; 2024 May; 6(5):101054. PubMed ID: 38681861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble urokinase-type plasminogen activator levels are related to plasma cytokine levels but have low predictive value for mortality in trauma patients.
    Timmermans K; Vaneker M; Scheffer GJ; Maassen P; Janssen S; Kox M; Pickkers P
    J Crit Care; 2015 Jun; 30(3):476-80. PubMed ID: 25721031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis.
    Garnæs E; Mortensen C; Hobolth L; Andersen O; Nehlin J; Møller S
    PLoS One; 2019; 14(8):e0220697. PubMed ID: 31465463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma soluble urokinase-type plasminogen activator receptor (P-suPAR) in the diagnostics between malignant and non-malignant pancreatic lesions.
    Aronen A; Aittoniemi J; Huttunen R; Nikkola A; Nikkola J; Limnell O; Sand J; Laukkarinen J
    Pancreatology; 2023 Mar; 23(2):213-217. PubMed ID: 36596714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.
    Kolho KL; Valtonen E; Rintamäki H; Savilahti E
    Scand J Gastroenterol; 2012 Sep; 47(8-9):951-5. PubMed ID: 22746351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.
    Huang F; Li Y; Xu R; Cheng A; Lv Y; Liu Q
    Mediators Inflamm; 2020; 2020():7850179. PubMed ID: 32322165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease.
    Vesterhus M; Nielsen MJ; Hov JR; Saffioti F; Manon-Jensen T; Leeming DJ; Moum B; Boberg KM; Pinzani M; Karlsen TH; Karsdal MA; Thorburn D
    JHEP Rep; 2021 Feb; 3(1):100178. PubMed ID: 33225252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases.
    Rocha HC; Vilela EG
    Gastroenterol Hepatol; 2022 Feb; 45(2):83-90. PubMed ID: 34023469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.
    El-Mekkawy MS; Saleh NY; Sonbol AA
    Indian J Pediatr; 2016 Jul; 83(7):661-9. PubMed ID: 26960717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis.
    Trauner M; Gindin Y; Jiang Z; Chung C; Subramanian GM; Myers RP; Gulamhusein A; Kowdley KV; Levy C; Goodman Z; Manns MP; Muir AJ; Bowlus CL
    JHEP Rep; 2020 Feb; 2(1):100060. PubMed ID: 32039401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.